Unlock instant, AI-driven research and patent intelligence for your innovation.

A3 adenosine receptor ligand for managing cytokine release syndrome

A technology of adenosine receptors and cells, applied in the field of immunotherapy

Inactive Publication Date: 2020-07-24
康菲生物制药有限公司
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Immunosuppression found to be effective in treating CRS, but it contradicts original goals of immunotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A3 adenosine receptor ligand for managing cytokine release syndrome
  • A3 adenosine receptor ligand for managing cytokine release syndrome
  • A3 adenosine receptor ligand for managing cytokine release syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0224] Example 1: Clinical studies of A3AR agonists: IB-MECA (CF101) and Cl-IB-MECA (CF102)

[0225] The clinical study (the "Study") is a randomized, two-tier, placebo-controlled, parallel-group study of the safety and efficacy of CF101 (a pharmaceutical composition containing IB-MECA as an active ingredient) and CF102. CF101 and CF102 were administered orally to immunotherapy patients with moderate to severe CRS. Patients were randomized to receive oral pills of CF101 or CF102 or a matching placebo.

[0226] Patients participating in the study had to meet a number of eligibility criteria (i.e., must meet criteria for human subjects to participate in the study), including (1) recurrent blood cancer and any recurrence after immunotherapy and (2) normal organ function.

[0227] The clinical outcome of improving CRS symptoms was determined by various relevant parameters, such as the frequency of CRS, especially grade 4 CRS (grading according to the National Cancer Institute Com...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides a method of managing cytokine release syndrome (CRS) in a subject undergoing immunotherapy treatment, the method comprises administering to the subject an amount of anA3 adenosine receptor (A3AR) ligand effective to manage one or more of (i) level of at least one inflammatory cytokine and (ii) at least one CRS symptom; wherein said management is without significantly affecting said immunotherapy treatment. Also provided by the present disclosure is an A3 AR ligand and a composition comprising the ligand for use in the management of cytokine release syndrome (CRS) in a subject undergoing immunotherapy treatment, said management comprises one or more of (i) managing level of at least one inflammatory cytokine and (ii) managing at least one CRS symptom; wherein said management is without significantly affecting said immunotherapy treatment.

Description

technical field [0001] The present invention relates to an immunotherapy, in particular to an A 3 Therapeutic use of adenosine receptor ligands in the treatment of immunological complications. Background technique [0002] Listed below are references that are considered relevant to the currently disclosed objectives: [0003] - Daniel W. Lee et al., Current Concepts in the Diagnosis and Treatment of Cytokine Release Syndrome, Journal of Blood, 124(2):188-195 (2014); [0004] -Miller, Victoria, and Passam Sapandi, Identifying and Treating Cytokine Release Syndrome, Oncology Nursing Forum, 44(2)125, Pittsburgh, 15275, Society for Oncology Nursing, 2017. [0005] Acknowledgment herein of the aforementioned references should not be construed to imply that these references are in any way relevant to the patentability of the objects disclosed herein. [0006] background [0007] Immunotherapy uses immune system mechanisms to fight cancer. One promising technique uses adoptiv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K9/00A61K31/4745A61K31/52A61P29/00
CPCA61K45/06A61K9/2018A61K31/4745A61K31/52A61P29/00A61K31/7076A61P37/02A61P35/02A61P35/00
Inventor 潘宁那·费许曼
Owner 康菲生物制药有限公司